Akero Therapeutics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2017

Location

South San Francisco CA US

Primary Industry

Biotechnology

About

Founded in 2017 and based in California, US, Akero Therapeutics, Inc. operates as a biotechnology that develops treatment of non-alcoholic steatohepatitis and other metabolic disorders that target the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis. In March 2024, Akero Therapeutics Inc. raised USD 319 million in a private placement, selling 11 million shares at USD 29 per share on the Nasdaq Global Select Market under the ticker symbol "AKRO". Akero Therapeutics Inc. has granted the underwriters a 30-day option to purchase up to an additional 1.65 million shares of common stock as part of the listing. Akero Therapeutics developes therapies for serious metabolic diseases, to improve patients' lives. The company with its lead program, Efruxifermin (EFX), focuses on addressing metabolic dysfunction-associated steatohepatitis (MASH).

Current Investors

Atlas Venture, Versant Ventures, Apple Tree Partners

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development

Website

www.akerotx.com

Company Stage

Mature

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.